Directorio
FRANCISCO JAVIER SALVADOR BOFILL
Categoría
Profesor Asociado CIS
Contacto
Correo electrónico
Departamento
Área
Medicina
Investigación
Grupo de investigación
ONCOLOGÍA MOLECULAR Y NUEVAS TERAPIAS (ONCOLOGÍA MOLECULAR)
Proyectos y contratos de investigación
Marcadores de cáncer stem cells en carcinoma microcítico de pulmón: valoración pronóstica y uso como dianas específicas para el desarrollo de terapias (PI-0051-2013 - Investigador/a)
Marcadores de Cancer Stem Cells en Carcinoma Microcítico de Pulmón: Valoración Pronóstica y Uso Como Dianas Específicas para el Desarrollo de Terapias (PI-0051-2013 - Investigador/a)
Libros publicados
Salvador-Bofill, Francisco Javier:
Tratamiento anti-HER 2 actualización. . . 2012. 978-84-7885-564-3
Tratamiento anti-HER 2 actualización. . . 2012. 978-84-7885-564-3
Virizuela-Echaburu, Juan Antonio;Palacios-Eito, Amalia;Ortiz-Gordillo, Maria Jose;Sanchez-Rovira, Pedro;Fernandez-Lopez,Auxiliadora;Bayo-Lozano, Eloísa;Jimenez-Orozco, Encarnacion;Alonso-Redondo, Enrique;Salvador-Bofill, Francisco Javier;Exposito-Hernandez, Jose;Trigo-Perez, Jose Manuel;Gomez-España, M.Auxiliadora:
ACTUALIZACION. MANUAL DE COMPETENCIAS DEL MEDICO ESPECIALISTA EN ONCOLOGIA RADIOTERAPICA. AGENCIA DE CALIDAD SANITARIA DE ANDALUCIA. 2010. 978-84-92466-58-0
ACTUALIZACION. MANUAL DE COMPETENCIAS DEL MEDICO ESPECIALISTA EN ONCOLOGIA RADIOTERAPICA. AGENCIA DE CALIDAD SANITARIA DE ANDALUCIA. 2010. 978-84-92466-58-0
Virizuela-Echaburu, Juan Antonio;Ortiz-Gordillo, Maria Jose;Sanchez-Rovira, Pedro;Fernandez-Lopez,Auxiliadora;Bayo-Lozano, Eloísa;Jimenez-Orozco, Encarnacion;Alonso-Redondo, Enrique;Salvador-Bofill, Francisco Javier;Exposito-Hernandez, Jose;Trigo-Perez, Jose Manuel;Gomez-España, M.Auxiliadora:
ACTUALIZACION DEL MANUAL DE COMPETENCIAS DEL MEDICO ESPECIALISTA EN ONCOLOGIA MEDICA. AGENCIA DE CALIDAD SANITARIA DE ANDALUCIA. 2010. 978-84-92466-59-7
ACTUALIZACION DEL MANUAL DE COMPETENCIAS DEL MEDICO ESPECIALISTA EN ONCOLOGIA MEDICA. AGENCIA DE CALIDAD SANITARIA DE ANDALUCIA. 2010. 978-84-92466-59-7
Virizuela-Echaburu, Juan Antonio;Alonso-Redondo, Enrique;Sanchez-Rovira, Pedro;Trigo-Perez, Jose Manuel;Bayo-Lozano, Eloísa;Exposito-Hernandez, Jose;Fernandez-Lopez, Maria Auxiliadora;Gomez-España, M.Auxiliadora;Jimenez-Orozco, Encarnacion;Ortiz-Gordillo, Maria Jose;Palacios-Eito, Amalia;Salvador-Bofill, Francisco Javier:
MANUAL DE COMPETENCIAS DEL /DE LA MEDICO/A ESPECIALISTA EN ONCOLOGIA RADIOTERAPICA. AGENCIA DE CALIDAD SANITARIA DE ANDALUCIA. 2007. 978-84-96714-46-5
MANUAL DE COMPETENCIAS DEL /DE LA MEDICO/A ESPECIALISTA EN ONCOLOGIA RADIOTERAPICA. AGENCIA DE CALIDAD SANITARIA DE ANDALUCIA. 2007. 978-84-96714-46-5
Capítulos en Libros
Salvador-Bofill, Francisco Javier:
Epidemiología y Etiología. Atlas Integral de Cáncer de Mama. Pág. 2-7. YOU&US, S.A.. YOU&US, S.A.. 2010.
Epidemiología y Etiología. Atlas Integral de Cáncer de Mama. Pág. 2-7. YOU&US, S.A.. YOU&US, S.A.. 2010.
Bernabé-Caro, Reyes;Salvador-Bofill, Francisco Javier:
FACTORES PREDICTIVOS DE RESPUESTA A INHIBIDORES DE TIROSINCINASA EN EL TRATAMIENTO DEL CANCER DE PULMON: MUTACIONES, EXPRESION EGFR, AMPLIFICACION, OT. Pág. 287-296. JUST IN TIME, S.L.. JUST IN TIME, S.L.. 2006.
FACTORES PREDICTIVOS DE RESPUESTA A INHIBIDORES DE TIROSINCINASA EN EL TRATAMIENTO DEL CANCER DE PULMON: MUTACIONES, EXPRESION EGFR, AMPLIFICACION, OT. Pág. 287-296. JUST IN TIME, S.L.. JUST IN TIME, S.L.. 2006.
Bernabé-Caro, Reyes;Fernandez-Parra,Eva Maria;Salvador-Bofill, Francisco Javier:
DIAGNOSTICO Y EVOLUCION DEL DOLOR ONCOLOGICO CON FENTANILO TTS EN LA PRACTICA CLINICA. Pág. 37-42. GRUPO EDITORIAL ENTHEOS. GRUPO EDITORIAL ENTHEOS. 2005.
DIAGNOSTICO Y EVOLUCION DEL DOLOR ONCOLOGICO CON FENTANILO TTS EN LA PRACTICA CLINICA. Pág. 37-42. GRUPO EDITORIAL ENTHEOS. GRUPO EDITORIAL ENTHEOS. 2005.
Asistencia a congresos
Salvador-Bofill, Francisco Javier:
Magnetic resonance diffusion as predictive value of response to tratment with chemo-radiotherapy in patients with locally advanced rectal cancer. Poster en Congreso. European Society for medical Oncology. Madrid. 2014
Magnetic resonance diffusion as predictive value of response to tratment with chemo-radiotherapy in patients with locally advanced rectal cancer. Poster en Congreso. European Society for medical Oncology. Madrid. 2014
Salvador-Bofill, Francisco Javier:
Study of lapatinib (T) in combination with trastuzumab (T) in women heavily pretreated with HER2-positive metastatic breast cancer (MBC). Poster en Congreso. 2013 ASCO Annual Meeting. Chicago, Estados Unidos de América. 2013
Study of lapatinib (T) in combination with trastuzumab (T) in women heavily pretreated with HER2-positive metastatic breast cancer (MBC). Poster en Congreso. 2013 ASCO Annual Meeting. Chicago, Estados Unidos de América. 2013
Salvador-Bofill, Francisco Javier:
Assessment of treatment response with fulvestrant (F) 500 mg in standard clinical practice through a retrospective study: NCT01509625.. Poster en Congreso. 2013 ASCO Annual Meeting. Chicago, Estados Unidos de América. 2013
Assessment of treatment response with fulvestrant (F) 500 mg in standard clinical practice through a retrospective study: NCT01509625.. Poster en Congreso. 2013 ASCO Annual Meeting. Chicago, Estados Unidos de América. 2013
Salvador-Bofill, Francisco Javier:
Cross-sectional observational study to describe the clinicopathological and biological characteristics and the management of patients with HER2+ metas. Poster en Congreso. 2012 ASCO Annual Meeting . Chicago. 2012
Cross-sectional observational study to describe the clinicopathological and biological characteristics and the management of patients with HER2+ metas. Poster en Congreso. 2012 ASCO Annual Meeting . Chicago. 2012
Ruiz-Borrego, Manuel;Salvador-Bofill, Francisco Javier;Valero-Arbizu, María;Vicente-Baz, David;Limon-Miron, Maria Luisa;Fuentes-paradera, Jose;Sabido-alvarez, Araceli;Calvo-garcia, Elisa:
¿Cisplatino, gencitabina y lapatinib en pacientes con cáncer metastásico Her-2+. Experiencia en la práctica clínica¿. Comunicación en congreso. XII Congreso de la Sociedad Española de Oncología Médica, Málaga 2011. . 2011
¿Cisplatino, gencitabina y lapatinib en pacientes con cáncer metastásico Her-2+. Experiencia en la práctica clínica¿. Comunicación en congreso. XII Congreso de la Sociedad Española de Oncología Médica, Málaga 2011. . 2011
Salvador-Bofill, Francisco Javier;Et Al.-,-:
PHASE II OPEN LABEL TRIAL BEVACIZUMAB IN COMBINATION WITH PACLITAXEL AND GEMCITABINE AS FIRST LINE IN PATIENTS WITH HER-2 NEGATIVE RECURRENT OR ME. Poster en Congreso. 33RD ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM (33) (33.2010.SAN ANTONIO, TEXAS, EEUU). SAN ANTONIO, TEXAS, EEUU. 2010
PHASE II OPEN LABEL TRIAL BEVACIZUMAB IN COMBINATION WITH PACLITAXEL AND GEMCITABINE AS FIRST LINE IN PATIENTS WITH HER-2 NEGATIVE RECURRENT OR ME. Poster en Congreso. 33RD ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM (33) (33.2010.SAN ANTONIO, TEXAS, EEUU). SAN ANTONIO, TEXAS, EEUU. 2010
Salvador-Bofill, Francisco Javier:
Cross-sectional observational study to describe the clinicopathological and biological characteristics and the management of patients with HER2+ metas. Poster en Congreso. . .
Cross-sectional observational study to describe the clinicopathological and biological characteristics and the management of patients with HER2+ metas. Poster en Congreso. . .
Salvador-Bofill, Francisco Javier:
Cross-sectional observational study to describe the clinicopathological and biological characteristics and the management of patients with HER2+ metas. Poster en Congreso. . .
Cross-sectional observational study to describe the clinicopathological and biological characteristics and the management of patients with HER2+ metas. Poster en Congreso. . .
Artículos publicados
Pecero-López, María Luisa;Salvador-Bofill, Francisco Javier;Molina-Pinelo, Sonia:
Long non-coding RNAs as monitoring tools and therapeutic targets in breast cancer.. Cellular oncology. 2018. Pág. 1-12. doi: 10.1007/s13402-018-0412-6.
Long non-coding RNAs as monitoring tools and therapeutic targets in breast cancer.. Cellular oncology. 2018. Pág. 1-12. doi: 10.1007/s13402-018-0412-6.
Blancas-López-Barajas, María Isabel;Salvador-Bofill, Francisco Javier:
Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice.. Clinical & Translational Oncology. 2017. 10.1007/s12094-017-1797-9.
Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice.. Clinical & Translational Oncology. 2017. 10.1007/s12094-017-1797-9.
Salvador-Bofill, Francisco Javier:
COST MINIMIZATION ANALYSIS OF TREATMENT WITH INTRAVENOUS OR SUBCUTANEOUS TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE BREAST CANCER IN SPAIN. Clinical & Translational Oncology. 2017. 10.1007/s12094-017-1684-4.
COST MINIMIZATION ANALYSIS OF TREATMENT WITH INTRAVENOUS OR SUBCUTANEOUS TRASTUZUMAB IN PATIENTS WITH HER2-POSITIVE BREAST CANCER IN SPAIN. Clinical & Translational Oncology. 2017. 10.1007/s12094-017-1684-4.
Salvador-Bofill, Francisco Javier:
Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions. Clinical & Translational Oncology. 2017. Vol: 19. Núm: 3. Pág. 341-356. 10.1007/s12094-016-1535-8.
Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions. Clinical & Translational Oncology. 2017. Vol: 19. Núm: 3. Pág. 341-356. 10.1007/s12094-016-1535-8.
Salvador-Bofill, Francisco Javier:
Defining the optimal sequence for the systemic treatment of metastatic breast cancer.. Clinical & Translational Oncology. 2016.
Defining the optimal sequence for the systemic treatment of metastatic breast cancer.. Clinical & Translational Oncology. 2016.
Salvador-Bofill, Francisco Javier:
Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast . Clinical & Translational Oncology. 2015. Vol: 17. Núm: 2. Pág. 160-166. 10.1007/s12094-014-1210-x.
Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast . Clinical & Translational Oncology. 2015. Vol: 17. Núm: 2. Pág. 160-166. 10.1007/s12094-014-1210-x.
Salvador-Bofill, Francisco Javier:
Bone turnover markers as predictive indicators of outcome in patients with breast and bone metastases treates with bisphosphonates: Results from a 2-y. Bone. 2014. Vol: 68. Núm: 68. Pág. 32-40.
Bone turnover markers as predictive indicators of outcome in patients with breast and bone metastases treates with bisphosphonates: Results from a 2-y. Bone. 2014. Vol: 68. Núm: 68. Pág. 32-40.
Salvador-Bofill, Francisco Javier:
362P ASSESSMENT OF TREATMENT RESPONSE WITH FULVESTRANT (F) 500 MG IN STANDARD CLINICAL PRACTICE THROUGH A RETROSPECTIVE STUDY: NCT01509625. Annals of Oncology. 2014.
362P ASSESSMENT OF TREATMENT RESPONSE WITH FULVESTRANT (F) 500 MG IN STANDARD CLINICAL PRACTICE THROUGH A RETROSPECTIVE STUDY: NCT01509625. Annals of Oncology. 2014.
Salvador-Bofill, Francisco Javier:
Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast. Journal of Clinical Oncology. 2013. Vol: 31. Núm: 20. Pág. 2593-2599. 10.1200/JCO.2012.46.9841.
Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast. Journal of Clinical Oncology. 2013. Vol: 31. Núm: 20. Pág. 2593-2599. 10.1200/JCO.2012.46.9841.
Salvador-Bofill, Francisco Javier;Grávalos, C;Alba-Conejo, Emilio;Salvado-bofill, Francisco Javier;Albanell, Joan;Barnadas, A:
Functions and workload of medical oncologists in Spain.. Clinical & Translational Oncology. 2012. Vol: 14. Núm: 6. Pág. 423-429.
Functions and workload of medical oncologists in Spain.. Clinical & Translational Oncology. 2012. Vol: 14. Núm: 6. Pág. 423-429.
Salvador-Bofill, Francisco Javier:
Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab. Breast Cancer Research. 2012. Vol: 13. Núm: 2. 10.1186/bcr3025.
Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab. Breast Cancer Research. 2012. Vol: 13. Núm: 2. 10.1186/bcr3025.
Salvador-Bofill, Francisco Javier;Salvador-Bofill, Francisco Javier;Alba-Conejo, Emilio;Grávalos, C;Albanell, Joan:
Pilot study on workload estimate in breast cancer, lung cancer and colorectal cancer in a Medical Oncology Service at Valme hospital.. Clinical & Translational Oncology. 2012. Vol: 14. Núm: 11. Pág. 820-826. 10.1007/s12094-012-0873-4.
Pilot study on workload estimate in breast cancer, lung cancer and colorectal cancer in a Medical Oncology Service at Valme hospital.. Clinical & Translational Oncology. 2012. Vol: 14. Núm: 11. Pág. 820-826. 10.1007/s12094-012-0873-4.
Calderón-Montaño, José Manuel;Burgos-Morón, Estefanía;Pérez-Guerrero, Concepción;Salvador-Bofill, Francisco Javier;Robles-Frias, Antonio;López-Lázaro, Miguel:
ROLE OF THE INTRACELLULAR PH IN THE METABOLIC SWITCH BETWEEN OXIDATIVE PHOSPHORYLATION AND AEROBIC GLYCOLYSIS - RELEVANCE TO CANCER. WebmedCentral.com. 2011. Vol: 2. Núm: 3.
ROLE OF THE INTRACELLULAR PH IN THE METABOLIC SWITCH BETWEEN OXIDATIVE PHOSPHORYLATION AND AEROBIC GLYCOLYSIS - RELEVANCE TO CANCER. WebmedCentral.com. 2011. Vol: 2. Núm: 3.
Fuentes Pradera-,J.;Salvador-Bofill, Francisco Javier;Grilo Reina-,A.;Lopez Ladron-,A.;Bernabe Caro-,R.;Fernandez Parra-,E.;Gallego-,I .;Rodriguez De La Borbolla-,M.:
CHRONOLOGY OF THE ARTERIAL HYPERTENSION ASSOCIATED WITH INHIBITING TREATMENTS OF VASCULAR ENDOTHELIUM GROWTH FACTOR RECEPTOR IN PATIENTS WITH CANCER. Journal of Clinical Oncology. 2010. Vol: 28. Núm: 15. Pág. E19638-E19638.
CHRONOLOGY OF THE ARTERIAL HYPERTENSION ASSOCIATED WITH INHIBITING TREATMENTS OF VASCULAR ENDOTHELIUM GROWTH FACTOR RECEPTOR IN PATIENTS WITH CANCER. Journal of Clinical Oncology. 2010. Vol: 28. Núm: 15. Pág. E19638-E19638.
Burgos-Morón, Estefanía;Calderón-Montaño, José Manuel;Salvador-Bofill, Francisco Javier;Robles-Frias, Antonio;López-Lázaro, Miguel:
THE DARK SIDE OF CURCUMIN.. International Journal of Cancer. 2010. Vol: 126. Núm: 7. Pág. 1771-1775.
THE DARK SIDE OF CURCUMIN.. International Journal of Cancer. 2010. Vol: 126. Núm: 7. Pág. 1771-1775.
Colomer-, Ramon;Alba-Conejo, Emilio;Trigo-Perez, Jose Manuel;Germa-,J.R.;Bellmunt-,J;Tabernero-,J.;Rosell-,R;Aranda-Aguilar, Enrique;Baselga-, Juan;Paz-Ares-Rodriguez, Luis Gonzaga;Martin-,M;Llombart-,A.;Rodríguez- Lescure-,A;Salvador-Bofill, Francisco Javier;Albanell-,J.;Isla-,D;Lomas-,M:
TREATMENT OF CANCER WITH ORAL DRUGS: A POSITION STATEMENT BY THE SPANISH SOCIETY OF MEDICAL ONCOLOGY (SEOM).. Annals of Oncology. 2010. Vol: 21. Núm: 2. Pág. 195-198.
TREATMENT OF CANCER WITH ORAL DRUGS: A POSITION STATEMENT BY THE SPANISH SOCIETY OF MEDICAL ONCOLOGY (SEOM).. Annals of Oncology. 2010. Vol: 21. Núm: 2. Pág. 195-198.
Moreno-Vega, Antonio;Chavarria-,N;Rubio-,J;Villandiego-,I;Estepa-,R;Gordon-,M;Salvador-Bofill, Francisco Javier;Jimenez-, E.:
PRIMARY BREAST SARCOMA: CLINICAL AND RETROSPECTIVE ANALYSIS OF CASES FROM JEREZ GENERAL HOSPITAL, SPAIN. Journal of Clinical Oncology. 2009. Vol: 27. Núm: 15S. Pág. E21526-E21526.
PRIMARY BREAST SARCOMA: CLINICAL AND RETROSPECTIVE ANALYSIS OF CASES FROM JEREZ GENERAL HOSPITAL, SPAIN. Journal of Clinical Oncology. 2009. Vol: 27. Núm: 15S. Pág. E21526-E21526.
Salvador-Bofill, Francisco Javier;Ruiz-,M;Bayo-,J;Lomas-,M;Moreno-,A;Valero-, M;Bernabé-,R.;Vicente-,D;Jimenez-, J.;Lopez-Ladron,A:
MULTICENTER STUDY OF WEEKLY TRASTUZUMAB, PACLITAXEL, AND CARBOPLATIN FOLLOWED BY A WEEK OF REST EVERY 28 DAYS IN PATIENTS WITH HER2+ METASTATIC BREAST. Journal of Clinical Oncology. 2008. Vol: 26. Núm: 15S. Pág. 1080-1080.
MULTICENTER STUDY OF WEEKLY TRASTUZUMAB, PACLITAXEL, AND CARBOPLATIN FOLLOWED BY A WEEK OF REST EVERY 28 DAYS IN PATIENTS WITH HER2+ METASTATIC BREAST. Journal of Clinical Oncology. 2008. Vol: 26. Núm: 15S. Pág. 1080-1080.
Lomas-Garrido, Maria De La Cabeza;Bayo-,J;Lomas-,M;Salvador-Bofill, Francisco Javier;Moreno-,A;Ruiz-,M;Rodriguez-, A.;Fuentes-, J;Fernandez-Freire,A;Bernabe-,R;Fernandez-,A:
A MULTICENTRE PHASE II STUDY TO EVALUATE SEQUENTIAL DOCETAXEL FOLLOWED BY CAPECITABINE TREATMENT IN ANTHRACYCLINE-PRETREATED HER-2-NEGATIVE PATIENTS W. Clinical & Translational Oncology. 2008. Vol: 10. Núm: 12. Pág. 817-825.
A MULTICENTRE PHASE II STUDY TO EVALUATE SEQUENTIAL DOCETAXEL FOLLOWED BY CAPECITABINE TREATMENT IN ANTHRACYCLINE-PRETREATED HER-2-NEGATIVE PATIENTS W. Clinical & Translational Oncology. 2008. Vol: 10. Núm: 12. Pág. 817-825.
Salvador-Bofill, Francisco Javier;Ruiz-Borrego, Manuel;Bayo-Calero, Juan Lucas;Lomas-,M;Moreno-Vega, Antonio;Bernabe-,R;Valero-, M;Vicente-Baz, David;Fuentes-, J;Lopez-Ladron,A:
MULTICENTER STUDY OF WEEKLY TRASTUZUMAB, PACLITAXEL AND CARBOPLATIN FOLLOWED BY A WEEK OF REST EVERY 28 DAYS IN PATIENTS WITH HER2+METASTATIC BREAST C. European Journal Of Cancer. Supplement. 2008. Vol: 6. Núm: 7. Pág. 172-173.
MULTICENTER STUDY OF WEEKLY TRASTUZUMAB, PACLITAXEL AND CARBOPLATIN FOLLOWED BY A WEEK OF REST EVERY 28 DAYS IN PATIENTS WITH HER2+METASTATIC BREAST C. European Journal Of Cancer. Supplement. 2008. Vol: 6. Núm: 7. Pág. 172-173.
Ruiz-,M;Salvador-Bofill, Francisco Javier;Bayo-,J;Lomas-,M;Moreno-, A.;Valero-, M;Bernabe-,R;Vicente-,D;Jimenez-, J.;Lopez-Ladron,A:
MULTICENTER STUDY OF WEEKLY TRASTUZUMAB, PACLITAXEL AND CARBOPLATIN FOLLOWED BY A WEEK OF REST EVERY 28 DAYS IN PATIENTS WITH HER2+ METASTATIC BREAST. Journal of Clinical Oncology. 2007. Vol: 25. Núm: 18. Pág. 1083-1083.
MULTICENTER STUDY OF WEEKLY TRASTUZUMAB, PACLITAXEL AND CARBOPLATIN FOLLOWED BY A WEEK OF REST EVERY 28 DAYS IN PATIENTS WITH HER2+ METASTATIC BREAST. Journal of Clinical Oncology. 2007. Vol: 25. Núm: 18. Pág. 1083-1083.
Bayo-,J;Lomas-,M;Salvador-Bofill, Francisco Javier;Ruiz-,M;Moreno-, A.:
DOCETAXEL (T) FOLLOWED BY CAPECITABINE (X) AS FIRST-LINE CHEMOTHERAPY IN PATIENTS (PTS) WITH METASTATIC BREAST CANCER (MBC): PRELIMINARY FINDINGS FROM. Journal of Clinical Oncology. 2006. Vol: 24. Núm: 18S. Pág. 10692-10692.
DOCETAXEL (T) FOLLOWED BY CAPECITABINE (X) AS FIRST-LINE CHEMOTHERAPY IN PATIENTS (PTS) WITH METASTATIC BREAST CANCER (MBC): PRELIMINARY FINDINGS FROM. Journal of Clinical Oncology. 2006. Vol: 24. Núm: 18S. Pág. 10692-10692.
Lomas-,M;Salvador-Bofill, Francisco Javier;Ruiz-,M;Bayo-,J:
SAFETY OF LONG-TERM ADMINISTRATION OF CAPECITABINE IN METASTATIC BREAST CANCER.. Journal of Clinical Oncology. 2006. Vol: 24. Núm: 18S. Pág. 10755-10755.
SAFETY OF LONG-TERM ADMINISTRATION OF CAPECITABINE IN METASTATIC BREAST CANCER.. Journal of Clinical Oncology. 2006. Vol: 24. Núm: 18S. Pág. 10755-10755.
Bayo-,J;Salvador-Bofill, Francisco Javier;Lomas-,M;Ruiz-,M;Baena-,J.;Vicente-,D;Bernabé-,R.;Pineda-, M:
DOCETAXEL FOLLOWED BY CAPECITABINE AS FIRST-LINE CHEMOTHERAPY IN METASTATIC BREAST CANCER PATIENTS: PRELIMINARY RESULTS. Journal of Clinical Oncology. 2005. Vol: 23. Núm: 16S. Pág. 854-854.
DOCETAXEL FOLLOWED BY CAPECITABINE AS FIRST-LINE CHEMOTHERAPY IN METASTATIC BREAST CANCER PATIENTS: PRELIMINARY RESULTS. Journal of Clinical Oncology. 2005. Vol: 23. Núm: 16S. Pág. 854-854.
Bernabé-Caro, Reyes;Salvador-Bofill, Francisco Javier:
TRATAMIENTO QUIMIOTERÁPICO ADYUVANTE Y NEOADYUVANTE DEL CÁNCER DE MAMA. Ciencia Ginecologika. 2004. Vol: 8. Núm: 2. Pág. 142-151.
TRATAMIENTO QUIMIOTERÁPICO ADYUVANTE Y NEOADYUVANTE DEL CÁNCER DE MAMA. Ciencia Ginecologika. 2004. Vol: 8. Núm: 2. Pág. 142-151.
Vicente-Baz, David;Mazo-,Jose Maria;Salvador-Bofill, Francisco Javier;Bernabé-Caro, Reyes;Moreno-Nogueira, Jose Andres:
DEGENERACIÓN CEREBELOSA PARANEOPLÁSICA Y CARCINOMA DE OVARIO. Oncología. 2001. Vol: 24. Núm: 8. Pág. 421-423.
DEGENERACIÓN CEREBELOSA PARANEOPLÁSICA Y CARCINOMA DE OVARIO. Oncología. 2001. Vol: 24. Núm: 8. Pág. 421-423.
Patentes
Domínguez-Cejudo, Mª Angeles;Salvador-Bofill, Francisco Javier;Garrigós, Carmen;Molina-Pinelo, Sonia: Modelo de expresión de UGT2B15 como predictor de respuesta a la neoadyuvancia en pacientes con cáncer de mama HER2 positivo y Receptores Hormonales ne. Número de patente:
